A placebo is an inactive substance or treatment designed to have no therapeutic effect, used as a control in clinical trials to assess the effect of an investigational product. In translation, the term appears in protocols, informed consent forms, blinding instructions, and clinical study reports where it must be distinguished from active comparators and from the investigational product itself.
Placebo is encountered in clinical trial protocols, participant-facing materials, investigational product labels, statistical analysis plans, and study reports. Translators must ensure that the term is rendered consistently in blinded materials and unblinding documentation, and that wording for placebo-controlled studies does not imply that the participant will receive no medical care.
A common mistake is translating placebo as 'fake medicine' or using a term that suggests ineffective or negligent treatment, which can confuse patients and erode trust. In blinded materials, revealing or hinting that one arm is inactive may undermine blinding. Inconsistent translation between subject-facing text and statistical reports also creates review issues.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →